PharmaCyte Biotech, Inc. — Form 10-K Summary
Reporting period: The filing is the annual report for the fiscal year ended April 30, 2017, compared with the year ended April 30, 2016. This differs from the request metadata’s “2016 Q4”; the filing also reports quarterly results for the quarter ended April 30, 2017. The report was signed July 27, 2017.
Business context
PharmaCyte is a clinical-stage biotechnology company developing cancer and diabetes cell therapies using its Cell-in-a-Box cellulose-based live-cell encapsulation technology. Its lead program is a proposed targeted chemotherapy for locally advanced, inoperable pancreatic cancer, using encapsulated cells with low-dose ifosfamide. Diabetes and cannabinoid-based cancer therapies are earlier-stage programs. The company had no commercial products or revenue.
Financial performance and liquidity
| Metric | FY ended April 30, 2017 | FY ended April 30, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $4.44 million | $6.07 million |
| Operating loss | $4.44 million | $6.07 million |
| Net loss | $4.44 million | $6.06 million |
| Net loss per share, basic and diluted | $0.01 | $0.01 |
| Net cash used in operations | $3.34 million | $4.35 million |
| Net cash from financing | $4.88 million | $3.57 million |
| Cash at year-end | $3.46 million | $1.92 million |
- Research and development expense was $1.18 million, down 16% from $1.41 million. Management attributed lower total expenses primarily to reduced R&D and consulting costs, including less stock-based consulting compensation.
- Cash and current assets were $3.46 million and $3.54 million, respectively; current liabilities were $580,248. The balance sheet showed no debt balance. Liabilities consisted principally of accounts payable and accrued expenses; the $150,000 license obligation reported in 2016 was paid by 2017.
- Total assets were $8.67 million, total liabilities $580,248, and accumulated deficit $89.14 million at April 30, 2017. No meaningful revenue margin can be assessed because there was no revenue.
- Management estimated cash expenditures at approximately $265,000 per month and stated that available cash and anticipated equity financing could fund operations through July 31, 2018. From May 1 through July 27, 2017, the company raised approximately $1.9 million in at-the-market stock sales.
Material changes versus the prior year
- Net loss narrowed by approximately $1.62 million, or 27%, while operating expenses declined by approximately $1.63 million.
- Operating cash use decreased by approximately $1.01 million. Financing proceeds increased by approximately $1.31 million, and year-end cash rose by $1.54 million.
- Common shares outstanding increased from 781.2 million to 905.3 million during the fiscal year, primarily reflecting equity financing and share-based compensation. The company reported 973.2 million shares outstanding as of July 27, 2017.
- The company filed a provisional cancer-therapy patent application in March 2017. Patents covering the licensed encapsulated-cell technology for cytochrome P450 expired March 27, 2017; the related Bavarian Nordic/GSF license also expired that date, and an extension was under negotiation.
Outlook, risks, and unusual items
- Following a January 2017 Pre-IND meeting, the FDA agreed with certain elements of the pancreatic-cancer development plan and identified tasks for the company. An IND had not yet been approved; the planned U.S. trial remained subject to FDA review and could be delayed, changed, or rejected.
- Management anticipated conducting clinical trials when cash permitted, potentially later in 2017 or the following year. The company stated that research and development activity could be scaled to available funding and that additional capital would be required. Its financing plan depends substantially on equity issuance, licensing, debt, or future product revenue; no assurance of adequate funding was given.
- Earlier European pancreatic-cancer studies were small, open-label trials. Reported survival and safety observations were not statistically validated and may not predict later-trial outcomes. In the Phase 2 study, the higher ifosfamide dose was associated with increased toxicity and no apparent survival advantage over the earlier study’s lower dose.
- The company relies heavily on Austrianova and other third parties for cell development, encapsulation, manufacturing, research, and clinical work. Related-party purchases from Austrianova subsidiaries were approximately $568,000 in FY2017. Future license royalties, milestone payments, and manufacturing commitments may apply as development progresses.
- Management identified material weaknesses in internal control over financial reporting, including ineffective governance and internal communication, inadequate control documentation, insufficient segregation of duties, and IT-control deficiencies. Disclosure controls and internal control over financial reporting were deemed ineffective; remediation work had begun but no changes had yet been implemented.
- The company reported no material pending litigation. Its financial statements were audited with an unqualified opinion; the auditor did not express an opinion on internal-control effectiveness.
Investor verification priorities
- Confirm the status and timing of the pancreatic-cancer IND, FDA feedback, required preclinical and manufacturing work, and any trial launch or enrollment.
- Verify current cash, monthly cash use, post-year-end financing, remaining S-3 capacity, and whether the stated July 2018 runway remains achievable without further dilution.
- Check the status of the expired Bavarian Nordic/GSF license and any negotiated extension, as well as the scope and progress of the March 2017 provisional patent application.
- Assess remediation of the disclosed material weaknesses and whether subsequent filings report effective controls.
- Review share-count changes, outstanding options and warrants, related-party payments, and contractual license and manufacturing milestones.